CN1310015A - Preparation method of anticancer medicine - Google Patents
Preparation method of anticancer medicine Download PDFInfo
- Publication number
- CN1310015A CN1310015A CN 01107100 CN01107100A CN1310015A CN 1310015 A CN1310015 A CN 1310015A CN 01107100 CN01107100 CN 01107100 CN 01107100 A CN01107100 A CN 01107100A CN 1310015 A CN1310015 A CN 1310015A
- Authority
- CN
- China
- Prior art keywords
- medicine
- days
- anticarcinogen
- rehabilitation
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 230000001093 anti-cancer Effects 0.000 title abstract description 4
- 238000002360 preparation method Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000002775 capsule Substances 0.000 claims abstract description 17
- 239000006187 pill Substances 0.000 claims abstract description 3
- 239000003005 anticarcinogenic agent Substances 0.000 claims description 32
- 241000628997 Flos Species 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 241000199223 Elaeocarpus kirtonii Species 0.000 claims description 3
- 235000009414 Elaeocarpus kirtonii Nutrition 0.000 claims description 3
- 235000013584 Tabebuia pallida Nutrition 0.000 claims description 3
- 239000010231 banlangen Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000002087 whitening effect Effects 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 49
- 201000007270 liver cancer Diseases 0.000 abstract description 4
- 208000014018 liver neoplasm Diseases 0.000 abstract description 4
- 208000019423 liver disease Diseases 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000007721 medicinal effect Effects 0.000 abstract description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 24
- 206010039509 Scab Diseases 0.000 description 16
- 238000013138 pruning Methods 0.000 description 13
- 239000012141 concentrate Substances 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 9
- 229960004397 cyclophosphamide Drugs 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 231100000403 acute toxicity Toxicity 0.000 description 7
- 230000007059 acute toxicity Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 241000555712 Forsythia Species 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a process for preparing anticancer medicine, which comprises peeling the bark of the tree trunk, boiling in water for 25-45 min, preparing into decoction or processing into tablets, pills, medicinal granules or capsules by the traditional technique, or processing the tree trunk into the main component of the medicine, the Chinese traditional medicine with heat-clearing and detoxicating function as the minor component, and then matching with licorice root, the anticancer medicine has good medical effect on various cancers in human body, especially on liver cancer caused by various liver diseases, small tumors can be recovered in 60 days, large tumors can be recovered in 150 days, and the recovery rate is about 80%.
Description
The invention belongs to the compound method of Chinese medicine, specifically is a kind of compound method of anticarcinogen.
At present, cancer remains a kind of incurable disease, is the healthy difficult medical problem of harm people.The whole world has up to ten million people to die from cancer every year approximately, and therefore, thoroughly beat cancer remains need the hold on target of unremitting effort struggle of people.
The objective of the invention is to provide a kind of compound method of anticarcinogen for people; Its anticarcinogen can prevent and treat especially hepatocarcinoma of most of cancers, and compound method is simple, and is easy to use.
The compound method of anticarcinogen of the present invention is that the whitewood whitening is removed crust, adds water boil then 25～45 minutes, makes decoction, also can adopt traditional handicraft to be processed into product forms such as tablet, pill, electuary or capsule.
In the such scheme, can also be the main component of medicine with Rhizoma Atractylodis macrocephalae's trunk, be submember with Chinese medicine with heat-clearing toxin-expelling functions, be equipped with Radix Glycyrrhizae again, be processed into product forms such as decoction, tablet, electuary or capsule through traditional handicraft.
In the such scheme, described Chinese medicine with heat-clearing toxin-expelling functions is any one or two or more the mixture in Fructus Forsythiae, Rhizoma Coptidis, Herba Artemisiae Annuae, Pericarpium Citri Reticulatae Viride, Flos Chrysanthemi, Flos Lonicerae, Radix Isatidis, the Radix Gentianae, described Rhizoma Atractylodis macrocephalae's trunk: Chinese medicine: the weight ratio of Radix Glycyrrhizae is 500: 20～80: 5～20.
Technical scheme of the present invention is the scientific formula that comes out through practice summary for many years, and in prescription, wherein, the Rhizoma Atractylodis macrocephalae is a thymelaeceae, and Rhizoma Atractylodis macrocephalae itself is the raw material of Chinese medicine (Lignum Aquilariae Resinatum), according to the medical function of Chinese Pharmacopoeia record Lignum Aquilariae Resinatum with cure mainly; Promoting the circulation of QI to relieve pain, warming middle-JIAO to arrest vomiting, helping inspiration to relieve asthma, be used for that breast abdominal distention is vexed, pain, gastrofrigid vomiting singultus, the QI rising in reverse order of suffering from a deficiency of the kidney dyspnea with rapid respiration etc.This shows, on China medicine history never the someone find Rhizoma Atractylodis macrocephalae's anti-cancer function, in traditional popular prescription, also have never heard of.Motherland's tcm theory and the inventor applies in a flexible way, and be bold in innovation, by facts have proved the whitewood whitening is removed crust (in the practice find crust is poisonous will affect the treatment), be boiled into decoction then hepatocarcinoma etc. is had better curative effect, and be the main component of medicine with Rhizoma Atractylodis macrocephalae's trunk, with the Chinese medicine with heat-clearing toxin-expelling functions is submember, be equipped with Radix Glycyrrhizae again, and be controlled at the scientific formula of proper proportion scope, the various cancers of inside of human body there is better medical effect, the hepatocarcinoma that (except that pulmonary carcinoma) causes various hepatopathys especially has special curative effect, the rehabilitation in 60 days of little tumor, rehabilitation in the big tumor 150 days, the rehabilitation rule accounts for about 80%, and in addition, this is filled a prescription to cirrhosis, liver ascites and hepatitis B, other multiple chronic disease all has unique curative effect in the human body.
The invention is further illustrated by the following examples, and the present invention is not limited only to described embodiment.
Embodiment one
With 1 kilogram on Rhizoma Atractylodis macrocephalae's trunk, cut into slices behind the crust of pruning, add water boil then, endured 20 minutes with slow fire, make decoction.Little tumour patient adhered to taking in 70 days can rehabilitation, rehabilitation in the big tumor 180 days, and the rehabilitation rule accounts for 70%.
Embodiment two
With 100 kilograms of crusts of pruning of Rhizoma Atractylodis macrocephalae's trunk, adopt traditional method through decocting in water, filtration, technology such as concentrate and be made into products such as decoction, tablet, electuary or capsule, little tumour patient adhered to taking in 70 days can rehabilitation, rehabilitation in the big tumor 180 days, and the rehabilitation rule accounts for about 70%.
Embodiment three
500 parts on Rhizoma Atractylodis macrocephalae's trunk of the selected crust of pruning, 45 parts of Fructus Forsythiaes, 15 parts in Radix Glycyrrhizae, adopt traditional method through decocting in water, filtration, technology such as concentrate and be made into products such as decoction, tablet, electuary or capsule, little tumour patient adhered to taking in 60 days can rehabilitation, rehabilitation in the big tumor 150 days, the rehabilitation rule accounts for about 80%.
Embodiment four
500 parts on Rhizoma Atractylodis macrocephalae's trunk of the selected crust of pruning, 65 parts of one Fructus Forsythiaes, 12 parts in Radix Glycyrrhizae, adopt traditional method through decocting in water, filtration, technology such as concentrate and be made into products such as decoction, tablet, electuary or capsule, little tumour patient adhered to taking in 60 days can rehabilitation, rehabilitation in the big tumor 150 days, the rehabilitation rule accounts for about 80%.
Embodiment five
500 parts on Rhizoma Atractylodis macrocephalae's trunk of the selected crust of pruning, 40 parts of Rhizoma Coptidis, 15 parts in Radix Glycyrrhizae, adopt traditional method through decocting in water, filtration, technology such as concentrate and be made into products such as decoction, tablet, electuary or capsule, little tumour patient adhered to taking in 60 days can rehabilitation, rehabilitation in the big tumor 150 days, the rehabilitation rule accounts for about 80%.
Embodiment six
500 parts on Rhizoma Atractylodis macrocephalae's trunk of the selected crust of pruning, 50 parts of Herba Artemisiae Annuaes, 18 parts in Radix Glycyrrhizae, adopt traditional method through decocting in water, filtration, technology such as concentrate and be made into products such as decoction, tablet, electuary or capsule, little tumour patient adhered to taking in 60 days can rehabilitation, rehabilitation in the big tumor 150 days, the rehabilitation rule accounts for about 80%.
Embodiment seven
500 parts on Rhizoma Atractylodis macrocephalae's trunk of the selected crust of pruning, 35 parts on Pericarpium Citri Reticulatae Viride, 10 parts in Radix Glycyrrhizae, adopt traditional method through decocting in water, filtration, technology such as concentrate and be made into products such as decoction, tablet, electuary or capsule, little tumour patient adhered to taking in 60 days can rehabilitation, rehabilitation in the big tumor 150 days, the rehabilitation rule accounts for about 80%.
Embodiment eight
500 parts on Rhizoma Atractylodis macrocephalae's trunk of the selected crust of pruning, 70 parts of Flos Chrysanthemis, 15 parts in Radix Glycyrrhizae, adopt traditional method through decocting in water, filtration, technology such as concentrate and be made into products such as decoction, tablet, electuary or capsule, little tumour patient adhered to taking in 60 days can rehabilitation, rehabilitation in the big tumor 150 days, the rehabilitation rule accounts for about 80%.
Embodiment nine
500 parts on Rhizoma Atractylodis macrocephalae's trunk of the selected crust of pruning, 65 parts of Flos Lonicerae, 12 parts in Radix Glycyrrhizae, adopt traditional method through decocting in water, filtration, technology such as concentrate and be made into products such as decoction, tablet, electuary or capsule, little tumour patient adhered to taking in 60 days can rehabilitation, rehabilitation in the big tumor 150 days, the rehabilitation rule accounts for about 80%.
Embodiment ten
500 parts on Rhizoma Atractylodis macrocephalae's trunk of the selected crust of pruning, 60 parts of Radix Isatidiss, 15 parts in Radix Glycyrrhizae, adopt traditional method through decocting in water, filtration, technology such as concentrate and be made into products such as decoction, tablet, electuary or capsule, little tumour patient adhered to taking in 60 days can rehabilitation, rehabilitation in the big tumor 150 days, the rehabilitation rule accounts for about 80%.
Embodiment 11
500 parts on Rhizoma Atractylodis macrocephalae's trunk of the selected crust of pruning, 50 parts of Radix Gentianaes, 10 parts in Radix Glycyrrhizae, adopt traditional method through decocting in water, filtration, technology such as concentrate and be made into products such as decoction, tablet, electuary or capsule, little tumour patient adhered to taking in 60 days can rehabilitation, rehabilitation in the big tumor 150 days, the rehabilitation rule accounts for about 80%.
Embodiment 12
500 parts on Rhizoma Atractylodis macrocephalae's trunk of the selected crust of pruning, 50 parts of Fructus Forsythiaes, 3 parts of Rhizoma Coptidis, 10 parts in Radix Glycyrrhizae, adopt traditional method through decocting in water, filtration, technology such as concentrate and be made into products such as decoction, tablet, electuary or capsule.
Embodiment 13
500 parts on Rhizoma Atractylodis macrocephalae's trunk of the selected crust of pruning, 50 parts of Fructus Forsythiaes, 5 parts of Flos Chrysanthemis, 3 parts of Rhizoma Coptidis, 10 parts in Radix Glycyrrhizae, adopt traditional method through decocting in water, filtration, technology such as concentrate and be made into products such as decoction, tablet, electuary or capsule.
Above-mentioned described Chinese medicine with heat-clearing toxin-expelling functions, with in Fructus Forsythiae, Rhizoma Coptidis, Herba Artemisiae Annuae, Pericarpium Citri Reticulatae Viride, Flos Chrysanthemi, Flos Lonicerae, Radix Isatidis, the Radix Gentianae any one for well, the mixture of two or more in them also can, just do not exemplify one by one at this.
Further introduce acute toxicity of the present invention and anti-tumor in vivo experiment situation below:
1. experiment material
1.1 medicine
Anticarcinogen of the present invention: be the brownish red suspension, the 1ml medicinal liquid is equivalent to the 5.839g crude drug in whole, faces with preceding that to be made into the suspension of desired concn with distilled water standby.
The hydrochloric acid cyclophosphamide: the 200mg/ bottle, to produce by last Hua Lian pharmaceutical Co. Ltd, lot number is 970611, is made into the solution for standby of desired concn before facing with normal saline.
1.2 animal
Be Kunming kind one-level mice, producing the quality certification number be No. 97007, the real Guan Zhidi of moving in river.Provide by Chengdu University of Traditional Chinese Medicine's Experimental Animal Center.
1.3 tumor strain
The scorching tumor (FAC) of mice transplantability Emhorn abdomen, sarcoma S180, available from Sichuan Province's antibiotic research pharmacological room; Hepatocarcinoma H22 is available from the Huaxi Medical Univ institute of oncology.
1.4 experimental apparatus
Electroruic??alance:Type??EB-3200D,Shimadzu??CorporationKYOTO,Japan,No.63294。
Inverted microscope: Chongqing 87137 factories produce.The medical clean work station of superclean bench: YJ875, be in December, 91 date of production, cleaning equipment company in Suzhou produces.
2. experimental situation
The clean laboratory animal environmental facility, the quality certification number is No. the 24103117th, the moving word of doctor.
3. experimental technique and result
3.1 acute toxicity testing
3.1.1 disposable administration is to the acute toxicity of mice
Find that after prerun the oral back of this medicine acute toxicity is very little, can't measure the LD50 of its disposable mouthful of newspaper, measure its maximal tolerated dose so change into, get body weight and be 20 of the mices of 18.1 ± 0.9g, male and female half and half, (volume is 04ml/10g to irritate this anticarcinogen of stomach 233.6g/kg, concentration is 5.839g/ml) once, day by day observe after the administration toxic reaction and the death condition of each animal in 7 days: put to death animal when experiment finishes, dissect its main organs of perusal: if any obvious pathological changes, make microscope inspection after then fixing, the results are shown in Table 1.
Table 1 is once irritated the acute toxicity of mouthful stomach administration to mice
| The animal sex | Number of animals (only) | Dosage (g/kg) | Body weight (g) before the medicine | 7 daily weights (g) behind the medicine | Animal dead number (only) | ANOMALOUS VARIATIONS |
| Male and female | ????10 ????10 | ????233.6 ????233.6 | ?18.3±1.0 ?18.3±0.7 | ?25.2±2.4 ?25.5±4.2 | ????0 ????0 | Do not have |
Experimental session, the outward appearance of each administration animal, behavior, hair, stool, mucosa etc. are Non Apparent Abnormality all, dissects each main organs of naked eyes, does not also find obviously unusual.As seen from Table 1, animal is all not dead in 7 days after administration.
3.1.2 continuous three administrations are to the acute toxicity of mice in one day
Get body weight and be 20 of the mices of 19.3+1.4g, male and female half and half, irritate this anticarcinogen of stomach 233.6g/kg continuous three times, be 5 hours each blanking time, making its accumulated dose is 700.8g/kg, observes toxic reaction and the death condition of each animal after the last administration: put to death animal when experiment finishes, dissect its main organs of perusal: if any obvious pathological changes, make microscope inspection after then fixing, the results are shown in Table 1.
Continuous three administrations are to the acute toxicity of mice in the table 2 one day
| The animal sex | Number of animals (only) | Dosage (g/kg) | Body weight (g) before the medicine | 7 daily weights (g) behind the medicine | Animal dead number (only) | ANOMALOUS VARIATIONS |
| Male and female | ????10 ????10 | ?700.8 ?700.8 | ?19.2±1.7 ?19.5±1.2 | ?25.5±2.3 ?26.3±3.7 | ?????0 ?????0 | Do not have |
Experimental session, the outward appearance of each administration animal, behavior, hair, stool, mucosa etc. are Non Apparent Abnormality all, separates towards each main organs of naked eyes, does not also find obviously unusual.As seen from Table 2, each administration animal is all not dead in 7 days after administration.
3.2 influence to mice transplanted tumor
3.2.1 influence to mouse transplanted sarcoma S180
Get body weight and be 82 of the mices of 18.4 ± 1.2g, female, be divided into 5 groups by table 3 at random, use this anticarcinogen 348,174,87g/kg respectively, cyclophosphamide 20mg/kg and equivalent distilled water, once a day, continuous 21 days.After administration the 8th day, under the sterile working, only give 5,000,000 cell/ of the right oxter subcutaneous injection S180 tumor cell suspension of mice.24h puts to death animal after the last administration, weighs, and carefully peels off the tumor body and claim weight in wet base, calculates its tumour inhibiting rate simultaneously.Its computing formula is:
Its result sees table 3 for details.
The influence of table 3 pair S180 tumor-bearing mice (x ± S)
| Group | Dosage (g/kg.d) | Before number of animals (only) medicine | Behind the medicine | Tumor heavy (g) | Suppression ratio (%) |
| Contrast anticarcinogen anticarcinogen anticarcinogen cyclophosphamide | ??87×21 ?174×21 ?348×21 ?20mg×21 | ????26 ????14 ????14 ????14 ????14 | ?22 ?13 ?13 ?14 ?10 | 1.97±1.09 1.74±1.01 1.54±0.92 1.26±0.56 *0.92±0.41 ** | ????11.7 ????21.8 ????36.0 ????53.3 |
Compare with matched group:
*P0.05,
*P0.01.(down together).
As seen from Table 3, this anticarcinogen 348g/kg * 21d can significantly suppress the growth of mouse transplanted sarcoma S180, and its suppression ratio 36% compares with matched group, and significance statistical discrepancy is arranged.Prompting, anticarcinogen of the present invention have the effect that suppresses mice S180 growth.
3.2.2 influence to mouse bearing liver cancer H22
Get body weight and be 83 of the mices of 19.8 ± 1.4g, female, be divided into 5 groups by table 4 at random, use this anticarcinogen 348,174,87g/kg respectively, cyclophosphamide 200mg/kg and equivalent normal saline, once a day, continuous 21 days.After administration the 8th day, under the sterile working, give mice right oxter subcutaneous injection H
226,000,000 cell/ of tumor cell suspension only.24h puts to death animal after the last administration, weighs, and carefully peels off the tumor body and claim weight in wet base, calculates its ratio of outflow simultaneously.The same 3.2.1 of the computing formula of its tumor control rate.Its result sees table 4 for details.
Table 4 couple mouse bearing liver cancer H
22Influence (x ± S)
| Group | Dosage (g/kg.d) | Number of animals (only) | Before the medicine | Behind the medicine | Heavy (g) suppression ratio (%) of tumor |
| Contrast anticarcinogen anticarcinogen anticarcinogen cyclophosphamide | ?87×21 ?174×21 ?348×21 ?20mg×21 | ????27 ????14 ????14 ????14 ????14 | ?26 ?10 ?13 ?13 ?10 | ?2.05±0.64 ?1.82+0.52??????11.2 ?1.77±0.91?????13.6 ?1.42±0.89 *???30.7 ?0.64±0.38 ***??68.8 |
As seen from Table 4, this anticarcinogen 348g/kg * 21d can significantly suppress mouse bearing liver cancer H
22Growth, its suppression ratio 30.7%, with matched group relatively, significance statistical discrepancy is arranged.
3.2.3 to hepatocarcinoma H
22The influence of tumor-bearing mice life cycle
Get body weight and be 64 of the mices of 20.2 ± 1.2g, female, be divided into 5 one groups by table 5 at random, use this anticarcinogen 348,174,87g/kg respectively, cyclophosphamide 20mg/kg and equivalent normal saline, once a day, continuous 21 days.After administration the 8th day, under the sterile working, to mouse peritoneal injection hepatocarcinoma H
226,400,000 cell/ of cell suspension only.After the last administration, day by day, write down the death time of each treated animal, be back 1 month of inoculation deadline.And calculate and prolong percentage rate its life cycle, its computing formula is:
Its result sees table 5 for details.
Table 5 couple hepatocarcinoma H
22The influence of tumor-bearing mice life cycle (x ± S)
| Group dosage (g/kg.d) | Number of animals (only) | Before the medicine | Behind the medicine | Tumor heavy (g) | Rate elongation (%) |
| Contrast anticarcinogen 87 * 21 anticarcinogens 174 * 21 anticarcinogens 348 * 21 cyclophosphamide 20mg * 21 | ????20 ????11 ????10 ????12 ????11 | ?20 ?11 ?10 ?12 ?11 | 15.0+4.2 18.5±3.8 *19.1±1.9 **20.3±4.8 **19.9±3.8 ** | ????23.0 ????27.3 ????35.5 ????53.3 |
As seen from Table 5, but the equal significant prolongation hepatocarcinoma H of each dosage group of this anticarcinogen
22The life cycle of tumor-bearing mice, its rate elongation is respectively 23.0%, 27.3% and 35.5%.Compare with matched group, significance statistical discrepancy is arranged.
3.2.4 influence to the ehrlich ascites tumor survival time of mice
Get body weight and be 76 of the mices of 20.4 ± 1.3g, be divided into 5 groups by table 6 at random, use this anticarcinogen 348,174,87g/kg respectively, cyclophosphamide 20mg/kg and equivalent normal saline, once a day, continuous 21 days.After administration the 8th day, under the sterile working, only to 4,800,000 cell/ of mouse peritoneal injection EAC cell suspension.The death condition of careful each treated animal of record after the last administration is observed deadline for inoculating back one month.And calculate and prolong percentage rate its life cycle, the same 3.2.3 of the computing formula of its tumor control rate.Its result sees table 6 for details.
The influence of table 6 pair EAC survival time of mice (x ± S)
| Group dosage (g/kg.d) | Number of animals (only) | Before the medicine | Behind the medicine | Tumor heavy (g) | Rate elongation (%) |
| Contrast anticarcinogen 87 * 21 anticarcinogens 174 * 21 anticarcinogens 348 * 21 cyclophosphamide 20mg * 21 | ????25 ????13 ????12 ????12 ????14 | ????25 ????13 ????12 ????12 ????14 | 14.2±4.9 16.8±5.4 18.8±5.7 *17.1±3.2 19.0±3.1 ** | ????17.9 ????31.8 ????20.1 ????33.9 |
From above-mentioned result of study as seen, to mice want 80, EAC, hepatocarcinoma H
22The obvious suppression effect is all arranged: both can significantly suppress murine sarcoma S180, hepatocarcinoma H
22The flat length of solid type, but significant prolongation EAC mice and hepatocarcinoma H again
22The life span of ascitic type tumor-bearing mice, this medicine does not have tangible acute toxicity simultaneously.Point out anticarcinogen of the present invention to have the wide development prospect.
Claims (3)
1, the compound method of anticarcinogen is characterized in that it being that the whitewood whitening is removed crust, adds water boil then 25～45 minutes, makes decoction or adopts traditional handicraft to be processed into tablet, pill, electuary or capsule.
2, the compound method of anticarcinogen according to claim 1, it is characterized in that with Rhizoma Atractylodis macrocephalae's trunk being the main component of medicine, with the Chinese medicine with heat-clearing toxin-expelling functions is submember, is equipped with Radix Glycyrrhizae again, is processed into decoction, tablet, electuary or capsule through traditional handicraft.
3, the compound method of anticarcinogen according to claim 2, it is characterized in that described Chinese medicine with heat-clearing toxin-expelling functions is any one or two or more the mixture in Fructus Forsythiae, Rhizoma Coptidis, Herba Artemisiae Annuae, Pericarpium Citri Reticulatae Viride, Flos Chrysanthemi, Flos Lonicerae, Radix Isatidis, the Radix Gentianae, described Rhizoma Atractylodis macrocephalae's trunk: Chinese medicine: the weight ratio of Radix Glycyrrhizae is 500: 20～80: 5～20.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01107100 CN1310015A (en) | 2001-02-08 | 2001-02-08 | Preparation method of anticancer medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01107100 CN1310015A (en) | 2001-02-08 | 2001-02-08 | Preparation method of anticancer medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1310015A true CN1310015A (en) | 2001-08-29 |
Family
ID=4656053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01107100 Pending CN1310015A (en) | 2001-02-08 | 2001-02-08 | Preparation method of anticancer medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1310015A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109331150A (en) * | 2018-12-06 | 2019-02-15 | 福建武夷山来生生物科技发展有限公司 | A kind of liver-nourishing Chinese medicinal composition |
-
2001
- 2001-02-08 CN CN 01107100 patent/CN1310015A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109331150A (en) * | 2018-12-06 | 2019-02-15 | 福建武夷山来生生物科技发展有限公司 | A kind of liver-nourishing Chinese medicinal composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104857435B (en) | A kind of Traditional Chinese medicine compound composition with antitumor activity and its preparation method and application | |
| CN104825783B (en) | Chinese medicine composition with antitumor activity and its preparation method and application | |
| CN1310015A (en) | Preparation method of anticancer medicine | |
| CN104825922B (en) | Chinese medicine composition with anti-colorectal carcinoma activity and its preparation method and application | |
| CN100334972C (en) | Body building health preparation and its producing method | |
| CN100337644C (en) | Chinese medicine for treating peptic ulcer and its prepn process | |
| CN1094052C (en) | Anticancer goose blood preparation | |
| CN104825784B (en) | A kind of Chinese medicine composition with anti-gastric cancer activity and its preparation method and application | |
| CN1289104C (en) | Anticancer medicine and its preparation | |
| CN104840716B (en) | Traditional Chinese medicine compound composition with anti-breast cancer activity and its preparation method and application | |
| CN100349585C (en) | Dampness dispersing, cancer resisting medicine, its preparation method and its application in the process for preparing anticancer medicine | |
| CN108404059A (en) | A kind of Chinese medicine composition for treating anti-type thyroid adenoma on liver-yang | |
| CN1262270C (en) | Application of levocarnitine and its derivative in preventing and treating high altitude diseases | |
| CN1256976C (en) | Anti-cancer Chinese medicinal composition and its preparing method | |
| CN1569085A (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN104840727B (en) | Chinese medicine composition with anti-cancer of the esophagus activity and its preparation method and application | |
| CN1289139C (en) | Medicine for treating colitis and its preparing method | |
| CN1679908A (en) | Chinese medicine for treating tumor and preparation thereof | |
| CN1559510A (en) | Compound medicine for treating Aids, cancer and its preparation method | |
| CN1772268A (en) | Medicine composition for raising immunity and its prepn and application | |
| CN1911357A (en) | Medicinal composition for treating hyperosteogency | |
| CN104840746B (en) | A kind of Chinese medicine composition with anti-lung cancer activity and its preparation method and application | |
| CN1836707A (en) | Medicine for treating tumour and its preparing method | |
| CN101164552A (en) | Centipede polysaccharide protein anti-tumor capsule and preparation method | |
| CN1449793A (en) | Anti-cancer medicine and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |